A new oral antiplatelet agent with potent antithrombotic properties: Comparison of DZ-697b with clopidogrel in a randomised phase I study

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Thrombosis and Haemostasis

• Publication date

  2009-10-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1160/TH09-06-0378PMID 20062928PMCID PMC3746984
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acu

  2009cited by this paper
• Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.

  2008cited by this paper
• Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose: The Reload With Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term With Dual Antiplatelet Therapy (RELOAD) Study

  2008cited by this paper
• Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study

  2008cited by this paper
• Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study.

  2008cited by this paper
• Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber

  2007cited by this paper
• Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients

  2007cited by this paper
• Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial

  2007cited by this paper
• Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.

  2007cited by this paper
• A novel anti‐ischemic nitric oxide donor (LA419) reduces thrombogenesis in healthy human subjects

  2007cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.

  2006cited by this paper
• FOCUS ISSUE: CARDIAC INTERVENTION Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting

  2006cited by this paper
• Pharmacokinetic/Pharmacodynamic Relationships for Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Subjects

  2006cited by this paper
• Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.

  2006cited by this paper
• Platelet GPIb‐IX‐V‐dependent signaling

  2005cited by this paper
• Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study*

  2005cited by this paper
• Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial

  2005cited by this paper
• Anti-Thrombotic Action of DZ-697b, a Novel Anti-Platelet Agent, on Photochemically Induced Thrombosis with Lower Bleeding Risk in Guinea Pigs.

  2005cited by this paper
• Pharmacological Profile of DZ-697b, a Novel Anti-Platelet Agent -Selective Inhibitor of vWF- and Collagen-Induced Platelet Aggregation.

  2005cited by this paper
• Signaling Through GP Ib-IX-V Activates αIIbβ3 Independently of Other Receptors

  2004cited by this paper
• Signaling through GP Ib-IX-V activates alpha IIb beta 3 independently of other receptors.

  2004cited by this paper
• Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy

  2004cited by this paper
• Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study

  2003cited by this paper
• Antithrombotic Effects of DX-9065a, a Direct Factor Xa Inhibitor

  2002cited by this paper
• Testing Platelet Activation With a Shear-Dependent Platelet Function Test Versus Aggregation-Based Tests: Relevance for Monitoring Long-Term Glycoprotein IIb/IIIa Inhibition

  2001cited by this paper
• Role of Fc receptor gamma-chain in platelet glycoprotein Ib-mediated signaling.

  2001cited by this paper
• Acute Antithrombotic Effect of a Front-Loaded Regimen of Clopidogrel in Patients With Atherosclerosis on Aspirin

  2000cited by this paper
• Antithrombotic effects of abciximab.

  2000cited by this paper
• Glycoprotein Ib-V-IX, a Receptor for von Willebrand Factor, Couples Physically and Functionally to the Fc Receptor γ-Chain, Fyn, and Lyn to Activate Human Platelets

  1999cited by this paper
• Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the Fc receptor gamma-chain, Fyn, and Lyn to activate human platelets.

  1999cited by this paper
• Single-dose pharmacodynamics of clopidogrel.

  1999cited by this paper
• Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.

  1998cited by this paper
• A Novel Association of Fc Receptor γ-Chain with Glycoprotein VI and Their Co-expression as a Collagen Receptor in Human Platelets*

  1997cited by this paper
• The Fc receptor γ‐chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen

  1997cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

  1996cited by this paper

• Rationale and Design of the SOTA-THROMBOSIS Trial (ATRU-VI): Antithrombotic Activities of Sotagliflozin compared to Empagliflozin.

  2025cites this paper
• In vitro and ex-vivo flow models for arterial thrombosis: a systematic review.

  2025cites this paper
• Should aspirin be replaced with ADP blockers and anti-GPVI to manage thrombosis?

  2022cites this paper
• Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic.

  2019cites this paper
• Targeting thrombogenicity and inflammation in chronic HIV infection

  2019cites this paper
• Crosstalk between Platelet and Bacteria: A Therapeutic Prospect.

  2019cites this paper
• The Role of 12-Lipoxygenase in the Regulation of Platelet Function

  2018cites this paper
• Badimon Perfusion Chamber: An Ex Vivo Model of Thrombosis.

  2018cites this paper
• Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis

  2018cites this paper
• Edinburgh Research Explorer Thrombin Exosite 1 Inhibition with JNJ-64179375 Inhibits Thrombus Formation in a Human Translational Model of Thrombosis

  2018cites this paper
• Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease

  2017cites this paper
• An exploration of the relationship between cardiovascular health, lifestyle factors and platelet function.

  2017cites this paper
• Guanosine exerts antiplatelet and antithrombotic properties through an adenosine-related cAMP-PKA signaling.

  2017cites this paper
• PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation

  2017cites this paper
• Platelet dependent thrombosis, blood thrombogenicity and response to antiplatelet therapy in health, ageing and type 2 diabetes mellitus

  2016cites this paper
• Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.

  2016cites this paper
• Antithrombotic properties of rafigrelide: a phase 1, open-label, non-randomised, single-sequence, crossover study

  2014cites this paper
• Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin

  2014cites this paper
• Newer Antiplatelet and Antithrombotic Drugs on the Horizon

  2013cites this paper
• Thrombosis Therapy: Focus on Antiplatelet Agents

  2013cites this paper
• Pharmacological inhibition of platelet reactivity. Clinical and pharmacodynamic effects.

  2013cites this paper
• Inhibitors of the interactions between collagen and its receptors on platelets.

  2012cites this paper
• Antiplatelet Agents

  2012cites this paper
• Newer agents in antiplatelet therapy: a review

  2012cites this paper
• Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study

  2012cites this paper
• Stroke prevention: from available antiplatelet drugs to novel molecular targets.

  2012cites this paper
• Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises

  2011cites this paper
• Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention

  2011cites this paper
• The Year in NonST-Segment Elevation Acute Coronary Syndrome

  2011cites this paper
• Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.

  2011cites this paper
• Tarek Ahmed bw.indd

  2011cites this paper
• Peri-operative management of antiplatelet therapy in patients with coronary artery disease

  2011cites this paper
• Magnetic Resonance Imaging of Neural and Pulmonary Vascular Function: A Dissertation

  2010cites this paper
• Atherosclerotic coronary artery disease

  2010cites this paper
• A time-tested ex vivo model of thrombosis: from pathophysiology to drug development and disease application.

  2010cites this paper
• Magnetic Resonance Imaging of Neural and Pulmonary Vascular Function

  2010cites this paper
• This material is the copyright of the original publisher. Unauthorised copying and distribution is prohibited. Antiplatelet Drugs - Do We Need New Options? With a Reappraisal of Direct Thromboxane Inhibitors

  2010cites this paper
• NP-184[2-(5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities

  2010cites this paper
• Antiplatelet Drugs — Do We Need New Options?

  2010cites this paper
• The year in non-ST-segment elevation acute coronary syndrome.

  2005cites this paper
• O R I G I N a L C L I N I C a L I N V E S T I G a T I O N Open Access

  year unknowncites this paper